Carlyle Group Adjusts Stake in Soleno Therapeutics

Ticker: SLNO · Form: SC 13D/A · Filed: 2024-10-21T00:00:00.000Z

Sentiment: neutral

Topics: ownership-change, sec-filing, amendment

TL;DR

Carlyle Group filed a 13D/A for Soleno Therapeutics, updating ownership details.

AI Summary

Carlyle Group Inc. and its affiliates, including Abingworth Bioventures VII LP, have filed an amendment to their Schedule 13D, indicating a change in their beneficial ownership of Soleno Therapeutics Inc. as of October 21, 2024. The filing details the group members involved in this reporting entity.

Why It Matters

This filing signals a potential shift in the ownership structure of Soleno Therapeutics, which could influence the company's strategic direction and market valuation.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate strategic shifts by major investors, potentially impacting stock price and company strategy.

Key Players & Entities

FAQ

What is the primary purpose of this SC 13D/A filing?

This filing is an amendment to a Schedule 13D, indicating a change in the beneficial ownership of Soleno Therapeutics Inc. by Carlyle Group Inc. and its affiliates.

Who are the key entities involved in this filing?

The filing involves Carlyle Group Inc. and its group members such as Abingworth Bioventures VII LP, Abingworth LLP, and Carlyle Genesis UK LLC, with Soleno Therapeutics Inc. as the subject company.

What is the filing date and as of date for this amendment?

The filing was made on October 21, 2024, and the date as of which the information is reported is also October 21, 2024.

What was Soleno Therapeutics Inc. formerly known as?

Soleno Therapeutics Inc. was formerly known as Capnia, Inc.

What is the business address of Soleno Therapeutics Inc.?

The business address of Soleno Therapeutics Inc. is 100 Marine Parkway, Suite 400, Redwood City, CA 94065.

Filing Stats: 2,786 words · 11 min read · ~9 pages · Grade level 10 · Accepted 2024-10-21 16:31:27

Key Financial Figures

Filing Documents

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 40,142,314 shares of Common Stock, which includes (i) 38,871,594 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuers quarterly report on Form 10-Q filed on August 7, 2024, (ii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof, (iii) 1,213,758 shares of Common Stock underlying the Prefunded Warrants, all of which are currently exercisable and (iv) 34,049 shares of Common Stock underlying a portion of the March 2022 Warrants, which are currently exercisable. Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition The Carlyle Group Inc. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Holdings I GP Inc. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Holdings I GP Sub L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Holdings I L.P. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 CG Subsidiary Holdings L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 TC Group, L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Investment Management L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,1

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : October 21, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CUSIP No. 834203200 13D Page 15 of 15 pages Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures VII LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory

View on Read The Filing